Dollars for Profs

Dig Into University Researchers' Outside Income and Conflicts of Interest

Published Dec. 6, 2019

This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.

Financial doc
Filing Type

Conflict of Interest

Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.

Should you be removed from our database? Contact us at [email protected]. Read more below.

Kevin Gillis

Exocytronics, Llc, Department: Na

Should you be removed from our database? Contact us at [email protected]. Read more below.

Disclosed Conflict of Interest with

ExoCytronics LLC

Disclosed Value
Listed Reason
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)

Dr. Gillis has a (b)(4) ownership stake in ExoCytronics, LLC. ExoCytronics will be the
primary awardee of this SBIR Phase II grant from NIH/NIMH, and ExoCytronics will make
a subcontract award to MU. The purpose of the award is to develop prototype devices
and software that may ultimately become products that ExoCytronics will sell.
It is the determination of the University of Missouri’s Conflict of Interest Committee and
designated official that Dr. Gillis’ interest in ExoCytronics could directly affect the design,
conduct and reporting of the subcontract.

Listed Research Project
Development of a prototype system for assaying exocytosis from individual cells using using transparent microelectrode arrays

The goal of this project is to develop robust and easy-to-use products that can assay secretion of hormones and neurotransmitter from individual cells 10- 100 fold faster and cheaper than current approaches. The devices will greatly accelerate the pace of medical research to understand how pharmaceuticals alter cell secretion. Other applications include calibrating the potency of pharmaceuticals used to treat neurological disorders, automated assays of food poisoning without the use of laboratory animals and improved detection of neurotoxin bioweapons.

Filed on November 03, 2015.

Tell us what you know about Kevin Gillis's disclosure

We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?

If you see an error in the database or a reason we should not disclose a record, please contact us at [email protected] and we'll evaluate it on a case-by-case basis.
Sources: National Institutes of Health, public records requests filed at multiple public state universities

Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.

Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.

ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.

Close Comment Creative Commons Donate Email Facebook Mobile Phone Podcast Print RSS Search Search Twitter WhatsApp
Current site Current page